



AGC Inc.

Financial Results for FY2023 Second Quarter

August 2, 2023

Event Summary

[Company Name]	AGC Inc.	
[Company ID]	5201-QCODE	
[Event Language]	JPN	
[Event Type]	Earnings Announcement	
[Event Name]	Financial Results for FY2023 Second Quarter	
[Fiscal Period]	FY2023 Q2	
[Date]	August 2, 2023	
[Number of Pages]	23	
[Time]	16:30 – 17:28 (Total: 58 minutes, Presentation: 26 minutes, Q&A: 32 minutes)	
[Venue]	Webcast	
[Number of Speakers]	4	
	Yoshinori Hirai	Representative Director, President & CEO
	Shinji Miyaji	Representative Director, Senior Executive Vice President, CFO
	Toshiro Kasuya	Senior Executive Officer, General Manager of Finance & Control Division
	Chikako Ogawa	General Manager of Corporate Communications & Investor Relations Division

Presentation

Ogawa: It is now time to start AGC Inc.'s financial results briefing for Q2 of the fiscal year ending December 31, 2023. I'm Chikako Ogawa from Corporate Communications & Investor Relations, serving as the moderator. Today's participants are Representative Director, President & CEO, Yoshinori Hirai; Representative Director, Senior Executive Vice President & CFO, Shinji Miyaji; and Managing Executive Officer, General Manager of Finance & Control, Toshiro Kasuya.

We will first have CFO, Miyaji, go over the financial results for Q2 FY2023. After that, CEO Hirai will explain AGC's initiatives and corporate value enhancement. We will then take your questions. We are planning to end at 5:30 PM. Your understanding and cooperation are appreciated. First, CFO, Miyaji.

Key points for today



Financial Results for 2Q FY2023

(YoY)

Net sales	985.3 bn JPY	(+7.0 bn JPY)
Operating profit	64.3 bn JPY	(▲51.0 bn JPY)
Profit for the period Attributable to owners of the parent	40.6 bn JPY	(▲30.6 bn JPY)

- Net sales increased thanks to higher sales prices in Automotive glass and Architectural glass, etc. as well as the impact of foreign exchange rates, despite the impact of the decline in sales prices for PVC.
- Operating profit decreased due to deteriorating manufacturing costs and higher raw material and fuel costs.

Outlook for FY2023 (Revised)

(vs. Feb. 8)

(YoY)

Net sales	2,050.0 bn JPY	(▲100 bn JPY)	(+14.1 bn JPY)
Operating profit	150.0 bn JPY	(▲40 bn JPY)	(▲33.9 bn JPY)

- We made downward revision due to the delayed market recovery of chlor-alkali products and the impact of delays in launching new lines for U.S. Biopharmaceuticals CDMO.

Miyaji: Good afternoon. I'm Miyaji, the CFO. Please turn to page three. These are the key points of today's briefing. Results for H1 FY2023 were affected by a decline in sales prices of PVC. But thanks to rising sales prices of automotive glass and architectural glass as well as the impact of exchange rates, net sales totaled JPY985.3 billion, an increase of JPY7 billion YoY. Operating profit decreased by JPY51 billion to JPY64.3 billion due to deterioration in manufacturing costs and the impact of higher raw materials and fuel costs. Net profit attributable to owners of the parent decreased by JPY30.6 billion to JPY40.6 billion. The sales forecast for the fiscal year has been lowered by JPY100 billion from the previous forecast to JPY2,050 billion in light of the delayed market recovery for chlor-alkali products and the delay in launching the new CDMO lines for biopharmaceuticals in the US. The operating profit forecast has been revised downward by JPY40 billion to JPY150 billion.

Highlights of the Financial Results for 2Q FY2023 (cumulative)



* FOREX impact was +51.9 billion JPY, change in the scope of consolidation was +0.7 billion JPY

(100 million JPY)

	FY2022		Change	Main factors in the change (+) Increasing factors (-) Decreasing factors
	1-2Q Total	1-2Q Total		
Net sales	9,783	9,853	+ 70*	(+) Increase in sales prices of Automotive glass and Architectural glass (+) Increase in shipments of Automotive glass (+) Yen depreciation (-) Decline in sales prices of PVC (-) Decrease in sales of Biopharmaceuticals CDMO and shipments of Fluorochemical-related products
Operating Profit	1,153	643	▲ 510	In addition to the above, (-) Deterioration in manufacturing costs (-) Increase in raw materials and fuel prices
Profit before tax	1,176	660	▲ 516	In addition to the above, (+) FOREX gain (+) Gain on sale of shares of subsidiaries and associates (-) Business structure improvement costs regarding Display business (Takasago site in Kansai Plant)
Profit for the period Attributable to owners of the parent	712	406	▲ 306	
FOREX (Average)	1USD	JPY 122.89	JPY 134.85	
	1EUR	JPY 134.25	JPY 145.79	
Crude oil (Dubai, Average)	USD/BBL	101.81	79.05	

©AGC Inc. 5

Page five. Net sales and operating profit were explained earlier.

Profit before tax decreased by JPY51.6 billion to JPY66 billion. Profit for the period attributable to owners of the parent was JPY40.6 billion.

YoY Performance Comparison by Business Segment



(100 million JPY)

	FY2022		FY2023		Change	
	1-2Q Total		1-2Q Total		(b)-(a)	
	(a)		(b)			
	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit
Architectural Glass	2,257	205	2,398	186	+ 141	▲ 19
Automotive	1,892	▲ 91	2,407	102	+ 515	+ 193
Electronics	1,481	92	1,419	29	▲ 62	▲ 63
Chemicals	3,336	824	2,828	309	▲ 509	▲ 514
Life Science	710	102	680	6	▲ 30	▲ 97
Ceramics/Other	435	25	394	14	▲ 41	▲ 11
Elimination	▲ 328	▲ 3	▲ 273	▲ 3	+ 55	+ 0
Total	9,783	1,153	9,853	643	+ 70	▲ 510

©AGC Inc. 6

Next, results by segment, please turn to page six. Architectural glass posted higher sales and lower profit.


Automotive posted higher sales and profit, and electronics, chemicals, and life science posted lower sales and profit.

Variance Analysis on OP(1-2Q.FY2023 vs. 1-2Q.FY2022)



51.0 bn JPY down from last year

(100 million JPY)



©AGC Inc.

7

Page seven. This is the YoY variance analysis of operating profit.

Sales volume, price, and product mix, minus JPY7.8 billion, while sales prices of automotive glass and architectural glass grew, sales prices of PVC declined. The purchase price of fuels and raw materials, minus JPY10.9 billion, reflecting an increase in prices of raw materials and fuels, including soda ash. Cost reduction and others, minus JPY32.3 billion. Manufacturing costs worsened in all segments other than electronics. Operating profit decreased from JPY115.3 billion to JPY64.3 billion, down JPY51 billion.

Consolidated Statement of Financial Position



	2022/12	2023/6	Change	
			(100 million JPY)	
Cash and cash equivalents	2,097	1,688	▲ 409	
Inventories	4,365	4,741	+ 376	
Property, plant and equipment, Goodwill and Intangible assets	15,148	16,151	+ 1,003	Foreign exchange fluctuation +94.8 billion yen
Other assets	6,530	6,998	+ 469	
Total assets	28,140	29,579	+ 1,438	Foreign exchange fluctuation +158.8 billion yen
Interest-bearing debt	6,502	7,083	+ 580	
Other liabilities	5,782	5,741	▲ 41	
Liabilities	12,284	12,824	+ 539	
Total equity attributable to owners of the parent	13,903	14,718	+ 816	
Non-controlling interests	1,953	2,037	+ 83	
Equity	15,856	16,755	+ 899	Foreign exchange fluctuation +89.3 billion yen
Total liabilities and equity	28,140	29,579	+ 1,438	
D/E ratio	0.41	0.42		

©AGC Inc. 8

Page eight. Consolidated statements of our financial position comparing with the end of December 2022, total assets were JPY2,957.9 billion, an increase of JPY143.8 billion. The D/E ratio was 0.42.

Consolidated Statement of Cash Flow



1-2Q Total	FY2022	FY2023	(100 million JPY)
Profit before tax	1,176	660	
Depreciation and amortization	902	859	
Increase(decrease) in working capital	▲ 527	▲ 403	
Others	▲ 321	▲ 221	
Cash flows from operating activities	1,230	894	
Cash flows from investing activities	▲ 667	▲ 881	
Free cash flow	562	13	
Changes in interest-bearing debt	182	222	
Dividends paid	▲ 289	▲ 233	
Others	▲ 130	▲ 525	
Cash flows from financing activities	▲ 237	▲ 536	
Effect of exchange rate changes on cash and cash equivalents	272	115	
Net increase(decrease) in cash and cash equivalents	597	▲ 409	

©AGC Inc. 9

Page nine, consolidated statement of cash flow.

Operating cash flow was JPY89.4 billion. Investing cash flow was negative JPY88.1 billion. Free cash flow as a result was JPY1.3 billion. Others in cash flows from financing activities which include a JPY31.5 billion expense for the acquisition of treasury stock.

CAPEX, Depreciation and R&D

1-2Q Total	FY2022	FY2023
CAPEX	1,051	1,052
Architectural Glass	75	100
Automotive	114	116
Electronics	416	293
Chemicals	314	396
Life Science	128	139
Ceramics/Other	6	10
Elimination	▲ 2	▲ 1
Depreciation	902	859
Architectural Glass	124	119
Automotive	154	156
Electronics	337	258
Chemicals	223	248
Life Science	54	68
Ceramics/Other	10	10
Elimination	▲ 1	▲ 1
R&D	249	270

(100 million JPY)

Main projects for CAPEX

- G11 investment in China (Electronics)
- Repairment for Display glass furnace (Electronics)
- Capacity enhancement of Electronic materials (Electronics)
- Capacity enhancement for Chlor-alkali in Southeast Asia (Chemicals)
- Capacity enhancement for Fluorochemical-related products (Chemicals)
- Capacity enhancement for Biopharmaceuticals CDMO and Small Molecule Pharmaceuticals and Agrochemicals CDMO (Life Science)

etc.

©AGC Inc. 10

Page 10. CapEx, depreciation, and R&D expenses. CapEx totaled JPY105.2 billion. Depreciation was JPY85.9 billion, and R&D expenses were JPY27 billion.

Architectural Glass Segment

1-2Q Total	FY2022	FY2023	Change
Net sales	2,257	2,398	+ 141*
Asia	681	759	+ 78
Europe & Americas	1,572	1,633	+ 61
(Inter-segment)	4	6	+ 2
Operating profit	205	186	▲ 19

* FOREX impact: +15.2 billion yen, Change in the Scope of Consolidation: +0.7 billion yen



Asia

- Despite shipments declined in all regions except Japan, net sales increased thanks to the rise in sales prices.



Europe & Americas

- Shipments declined in Europe, which was affected by the economic slowdown, but net sales increased thanks to the rise in sales prices and the impact of foreign exchange rates.
- Manufacturing costs deteriorated.

Variance Analysis on OP

(100 million JPY)



Ratio of sub-segment to the operating profit (before common expense allocation)



©AGC Inc. 12

Next, some details by segment. Please turn to page 12.

Starting with architectural glass, net sales for the first six months totaled JPY239.8 billion; operating profit, JPY18.6 billion. In Asia, shipments decreased in regions other than Japan. But through the increase in sales prices, sales increased by JPY7.8 billion YoY at JPY75.9 billion. In Europe and Americas saw the shipments decreased in Europe due to the economic slowdown. Sales increased by JPY6.1 billion to JPY163.3 billion due

to higher sales prices and the impact of exchange rates. As for operating profit, manufacturing costs worsened due to an increase in the unit price of inventory due to last year's operation adjustment in Europe. As for segment profit, Asia accounted for 40% and Europe and the Americas, 60%.


Automotive Segment



(100 million JPY)

1-2Q累計	FY2022	FY2023	Change
Net sales	1,892	2,407	+ 515*
Automotive	1,891	2,405	+ 514
(Inter-segment)	1	2	+ 1
Operating profit	▲ 91	102	+ 193

* FOREX impact: +13.3 billion yen, Change in the Scope of Consolidation: No impact



Automotive Glass

- The group's shipments increased as the automobile production increased.
- Net sales and operating profit increased thanks to the rise in sales prices, improvement of product mix and foreign exchange effects.

Page 13. Automotive. Net sales, JPY240.7 billion; operating profit, JPY10.2 billion. Shipments from the AGC Group increased as the number of automobile production increased globally. In addition, higher sales prices and improvements in the product mix and the impact of exchange rates contributed to a YoY increase in both sales and profit.

Electronics Segment



(100 million JPY)

1-2Q Total	FY2022	FY2023	Change
Net sales	1,481	1,419	▲ 62*
Display	870	783	▲ 87
Electronic Materials	600	631	+ 30
(Inter-segment)	11	5	▲ 6
Operating profit	92	29	▲ 63



* FOREX impact: +3.7 billion yen, Change in the Scope of Consolidation: No impact

Display

- Shipments of LCD glass substrates decreased.
- Raw materials and fuel costs increased.

Electronic Materials

- Sales increased thanks to robust shipments of EUV mask blanks and other products, as well as the impact of foreign exchange rates.



©AGC Inc.

14

Page 14. Electronics.

Net sales, JPY141.9 billion; operating profit JPY2.9 billion. Sales of displays decreased by JPY8.7 billion to JPY78.3 billion due to declining shipments of LCD glass substrates. The shipments of LCD glass substrates for the latest three months increased by around 10% over Q1, while sales prices remained almost unchanged. Electronic materials were affected by the slump in the semiconductor and smartphone markets but continued strong shipments of EUV photomask and the impact of exchange rates led to a YoY increase in net sales of JPY3 billion at JPY63.1 billion. Operating profit declined YoY due to such factors as the impact of higher fuel and raw materials costs despite steady sales of electronic materials.

Due to the impairment loss in the display business last year, depreciation expenses decreased significantly this fiscal year but impact from the deterioration in manufacturing costs due to lower facility utilization rates, improvements in cost reduction, and others was limited. The ratio of sub-segment to operating profit was electronic materials, 140%, and displays minus 40%.

Reference:

Progress of Display business earnings improvement



- We aim for business turnaround by strengthening competitiveness through technological innovation and implementing pricing policies, in addition to structural improvement measures.



Targeting ROCE of 10% or more at an early stage

©AGC Inc. 15

Please turn to page 15. The progress of measures to improve display business earnings improvement.

As you can see on the left-hand side, we are implementing business structure reforms based on the policies already announced. In addition, we will strengthen our competitiveness through technological innovation and also, we'll work on revisiting and revising our policy on pricing. By steadily promoting these three pillars, we aim to achieve a ROCE of 10% or higher at an early stage.

Chemicals Segment



(100 million JPY)

1-2Q Total	FY2022	FY2023	Change
Net sales	3,336	2,828	▲ 509*
Essential Chemicals	2,515	2,008	▲ 507
Performance Chemicals	796	798	+ 3
(Inter-segment)	26	22	▲ 4
Operating profit	824	309	▲ 514

* FOREX impact: +15.3 billion yen, Change in the Scope of Consolidation: No impact




Essential Chemicals

- Sales prices of PVC and other products declined.

Performance Chemicals

- Net sales remained at the same level as the previous year due to the rise in sales prices and foreign exchange effects, despite a decrease in shipments of Fluorochemical-related products.



©AGC Inc. 16

Please turn to page 16. Next, I will discuss the chemicals segment.

Net sales were JPY282.8 billion, and operating profit was JPY30.9 billion. Sales of essential chemicals decreased JPY50.7 billion to JPY200.8 billion due to lower sales price of PVCs and other products. Performance chemicals sales increased JPY300 million to JPY79.8 billion due to higher sales price and the effect of FX, despite a decrease in shipments of fluorochemical-related products. The ratio of the subsegment to OP and chemicals was 50% for essential chemicals and 50% for performance chemicals.

I would like to provide a supplemental explanation of the market for chlorine alkaline in Southeast Asia. The market for caustic soda and PVC declined due to the slow economic recovery, mainly in China and the United States. Although the price of ethylene, the raw material, declined, the PVC spread narrowed due to the significant impact of the sluggish product market.

Life Science Segment



	(100 million JPY)		
1-2Q Total	FY2022	FY2023	Change
Net sales	710	680	▲ 30*
Life Science	692	667	▲ 25
(Inter-segment)	18	13	▲ 5
Operating profit	102	6	▲ 97

* FOREX impact: +4.2 billion yen, Change in the Scope of Consolidation: No impact



Life Science

- Sales of Biopharmaceuticals CDMO decreased due to the disappearance of special demand for products related to the anti-coronavirus applications, reduced inflows of funds into biotech ventures and delays in launching new lines for Biopharmaceuticals CDMO in the U.S.
- Upfront costs incurred associated with capacity expansion in the biopharmaceutical field.

Please refer to page 18. Finally, let me talk about life science.

Sales in this segment totaled JPY68 billion, and operating profit was JPY600 million. Sales of biopharmaceutical CDMO decreased by JPY3 billion to JPY68 billion due to the loss of special demand for COVID-19, a decrease in funding for bioventures and a decline in contract sales due to a delay in the launch of a new biopharmaceutical CDMO production line in the US. Operating profit decreased due to the previously mentioned decline in sales as well as the upfront costs associated with the expansion of biopharmaceutical CDMO capacity.

On the next page, I will explain the current situation and business forecast for our biopharmaceutical CDMO business.

Reference: Current Situation and Outlook of Biopharmaceuticals CDMO



- Europe and Japan remains steady; the U.S. has been in a struggle.
- Performance is expected to improve in 2024 onward due to market recovery and improved operations at newly launched lines in the U.S.



©AGC Inc. 19

Please turn to page 19.

The biopharmaceutical CDMO business is performing well in Europe and Japan. However, it is struggling in the US, which is the largest issue. The biggest issue is the delay in the launch of new production lines in the US. We are taking drastic measures to normalize sales by the end of H2. We expect business performance to improve in 2024 and beyond as the market recovery shall also contribute to this improvement.

Profit contribution of Strategic Businesses



- FY2023 will be affected by adjustments in the semiconductor and smartphone markets, in addition to the poor performance of Biopharmaceuticals CDMO in the U.S.

(100 million yen)



©AGC Inc. 20

Please turn to page 20. Next, I will explain the performance of the strategic business.

Overall sales of the strategic businesses for H1 totaled JPY147.3 billion, an increase of JPY800 million. On the other hand, operating profit was JPY17.4 billion, a decrease of JPY10.3 billion. In addition to the poor performance of the Biopharmaceutical CDMO in the US, which I explained earlier, electronics was affected by the sluggish semiconductor and smartphone markets.

YoY Performance Comparison by Geographic Segment



1-2Q Total	FY2022	FY2023	Change	(100 million JPY)
Net sales	9,783	9,853	+ 70	FOREX impact : +51.9 bn JPY Change in the scope of consolidation : +0.7 bn JPY
Japan &Asia	6,347	6,055	▲ 292	
Americas	971	1,098	+ 127	
Europe	2,465	2,700	+ 235	
Operating profit	1,153	643	▲ 510	
Japan &Asia	1,137	631	▲ 506	
Americas	43	▲ 4	▲ 46	
Europe	172	243	+ 71	
Cross-regional common expenses	▲ 199	▲ 227	▲ 28	

©AGC Inc. 21

Please turn to page 21. This page shows the performance comparison by geographic segment.

FY2023 Outlook



- Operating profit is expected to decrease from the previous year and from the initial forecast due to the delayed market recovery of chlor-alkali products, as well as the significant impact of delay in launching new lines for U.S. Biopharmaceuticals CDMO.

	FY2022	FY2023e As of Aug 2, 2023	FY2023e As of Feb 8, 2023	(100 million JPY)
Net sales	20,359	20,500	21,500	
(First half)	9,783	9,853	10,300	
Operating profit	1,839	1,500	1,900	
(First half)	1,153	643	750	
Profit before tax	585	1,070	1,470	
Profit for the year attributable to owners of the parent	▲ 32	590	870	
Dividend (JPY/share)	210	210	210	
Operating profit margin	9.0%	7.3%	8.8%	
ROE	-	4.2%	6.3% *	
FOREX (Average) 1 USD	JPY 131.4	JPY 135.0	JPY 125.0	
1 EUR	JPY 138.0	JPY 150.0	JPY 135.0	
Crude oil (Dubai, Average) USD/BBL	96.3	81.0	85.0	
Ethylene (CFR SEA) USD/MT	1,054	870	1,000	


* ROE of FY2023e is calculated using the figures of Profit for the year attributable to owners of the parent as of Dec 31, 2022

©AGC Inc. 23

Please move on to page 23. I will now explain the full-year forecast.

As mentioned at the beginning of this presentation, we have made a downward revision to net sales and operating profit against the announcement from February 8. We now forecast sales of JPY2.05 trillion, up JPY14.1 billion; an operating profit of JPY150 billion, down JPY33.9 billion; profit before tax as JPY107 billion, up JPY48.5 billion; and profit attributable to owners of the parent, JPY59 billion, up JPY62.2 billion. FX assumption for the full year was revised to JPY135 to the US dollar and JPY150 to the euro. We also revised our full-year forecast for Dubai crude oil price to USD81 per barrel.

2023 Operating Profit Forecast



*Operating profit trends for 2022-23 are estimated in units of 5 billion yen, so totals do not match.

©AGC Inc. 24

Please move on to page 24. Now I would like to explain the change in the operating profit forecast more in detail.

Compared to the forecast announced on February 8, the automotive business is expected to exceed the forecast. However, the chlor-alkali market and strategic business are expected to fall short of the forecast. Please be aware that the forecast figures in the waterfall chart are estimates and units of JPY5 billion, and so the totals may not necessarily add up.

Outlook breakdown by Segment (Net sales and Operating profit)



- Although Automotive exceeded initial expectations, the forecasts were revised downward as Electronics, Chemicals, and Life Science fell short of initial expectations.

(100 million JPY)

	FY2022 (a)		FY2023e (b) As of Aug 2, 2023		Change (b)-(a)		FY2023e(c) As of Feb 2, 2023		Change (b)-(c)	
	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit
Architectural Glass	4,837	327	4,800	360	▲ 37	+ 33	+ 5,000	360	▲ 200	+ 0
Automotive	4,178	▲ 98	4,700	170	+ 522	+ 268	+ 4,700	80	+ 0	+ 90
Electronics	3,072	147	3,300	250	+ 228	+ 103	+ 3,400	380	▲ 100	▲ 130
Chemicals	6,604	1,261	6,000	710	▲ 604	▲ 551	+ 6,500	850	▲ 500	▲ 140
Life Science	1,418	169	1,350	▲ 10	▲ 68	▲ 179	+ 1,600	210	▲ 250	▲ 220
Ceramics/Other	866	37	850	20	▲ 16	▲ 17	+ 800	20	+ 50	+ 0
Elimination	▲ 616	▲ 3	▲ 500	0	+ 116	+ 3	▲ 500	0	+ 0	+ 0
Total	20,359	1,839	20,500	1,500	+ 141	▲ 339	+ 21,500	1,900	▲ 1,000	▲ 400

©AGC Inc.

25

Please turn to page 25. Next, I will explain the key points of the revised forecast by segment.

We have lowered our consolidated sales forecast by JPY100 billion with downward provisions in architectural glass, electronics, chemicals, and life science. We have lowered our consolidated OP forecast by JPY40 billion with an upward revision in automotive and a downward revision in electronics, chemicals, and life science.

2H Outlook by Business Segment (1)



Outlook for FY2023 2H (vs 2023 1H)

Architectural Glass			Automotive			Electronics		
Asia <ul style="list-style-type: none"> ■ Shipments are expected to be robust for the factors such as growing demand for high heat-insulating and shielding glass. 			<ul style="list-style-type: none"> ■ Although the effects of the ongoing supply shortage of semiconductors and other components will continue to ease, and the effects of the pricing policy that has been pursued for some time will contribute, the business is expected to be affected by seasonal declines in shipments. 			Display <ul style="list-style-type: none"> ■ Shipments of LCD glass substrates will increase due to recovery in demand for LCD panels. ■ Shipments of specialty glass for display will increase as orders from major customers grow. 		
Europe & Americas <ul style="list-style-type: none"> ■ Despite concerns about inflation and economic slowdown in Europe, replacement demand for high heat-insulating glass for energy savings will support shipments. 						Electronic Materials <ul style="list-style-type: none"> ■ Shipments of optoelectronics materials will increase due to demand season, despite the slowdown in the smartphone market. ■ Shipments of semiconductor-related products will increase mainly photomask blanks for EUV. 		

©AGC Inc.

26

Please turn to page 26. I will now explain the key points of the H2 forecast for each segment.

For architectural glass in Asia, shipments are expected to remain firm due to increased demand for high heat insulating and shielding glass. In Europe, despite concerns about inflation and economic slowdown, we expect shipments to be supported by demand for replacement with high heat insulating glass to reduce energy consumption.

Next is automotive. The continued recovery from the supply shortage of components for semiconductors and other products as well as the effects of our ongoing pricing policy will contribute. But we expect shipments to be impacted by seasonal declines.

Next is electronics and display. Shipments of LCD glass substrates are expected to increase due to a recovery in demand. The shipment volume of LCD glass substrates in Q3 is expected to increase by a low single-digit percentage compared with Q2. Shipments of specialty glass for display are expected to increase due to an expansion of orders from major customers. Among electronic materials, shipments of optoelectronics components are expected to increase during the demand season despite the slowdown in the smartphone market. In semiconductor-related products, shipments are expected to increase, centered on photomask blanks for EUV.

2H Outlook by Business Segment (2)

Outlook for FY2023 2H (vs 2023 1H)

Chemicals

Essential Chemicals

- Market recovery has been delayed due to slow economic recovery in China and the U.S., but the market will slowly recover along with the economic recovery.

Performance Chemicals

- Although the slowdown in the semiconductor and smartphone markets will cause fluorine-related products for some applications to level off, shipments will increase due to strong demand for products for transportation machinery and other applications.

Life Science

- Although sales of Small Molecule Pharmaceuticals and Agrochemicals CDMO will remain strong, in Biopharmaceuticals CDMO, the impact of the disappearance of special demand for products related to the anti-coronavirus applications and reduced inflows of funds into biotech ventures will continue.
- The newly production lines for Biopharmaceuticals CDMO in the U.S. will be expected to improve during the second half of FY2023.

©AGC Inc. 27

Please turn to page 27. Next is chemicals.


In essential chemicals, the market is expected to recover gradually as the economy recovers. However, not a dramatic recovery. In performance chemicals, the semiconductor and smartphone markets are slowing down, and the demand for fluorochemical-related products is expected to reach a standstill. However, the product demand for the transportation equipment sector is expected to increase.

Next is life science. Although small molecule pharmaceuticals and agrochemical CDMO are expected to remain firm, the impact of the disappearance of special demand for COVID-19 in biopharmaceutical CDMO and reduced funding for bioventures is expected to continue. In addition, as explained earlier, the new production line for biopharmaceutical CDMO in the US is expected to improve, i.e., normalize in H2.

Outlook of Strategic businesses



- Sales growth is expected to be sluggish and profit is expected to decline in 2023.
- The businesses will return to growth trajectory after 2024 along with a recovery in biopharmaceutical CDMO and expansion of semiconductor-related products such as EUV mask blanks.



Please turn to page 28. In strategic businesses, sales are expected to be sluggish, and earnings are expected to decline in 2023. But from 2024 onwards, we expect to return to our growth trajectory due to a recovery in biopharmaceutical CDMO sales and expansion of semiconductor-related products, such as photomask blanks for EUV.

CAPEX, Depreciation and R&D



Full year	FY2022	FY2023e	(100 million yen)
CAPEX	2,366	3,000	
Architectural Glass	175	250	
Automotive	298	270	
Electronics	800	930	
Chemicals	649	950	
Life Science	431	580	
Ceramics/Other	14	20	
Elimination	▲ 2	0	
Depreciation	1,857	1,880	
Architectural Glass	239	240	
Automotive	325	330	
Electronics	684	620	
Chemicals	475	520	
Life Science	115	150	
Chemicals	19	20	
Elimination	▲ 1	0	
R&D	523	580	

Main projects for CAPEX

- G11 investment in China (Electronics)
- Capacity enhancement of Electronic materials (Electronics)
- Capacity enhancement for Chlor-alkali in Southeast Asia (Chemicals)
- Capacity enhancement of Biopharmaceuticals CDMO (Life Science)
- etc.

©AGC Inc. 29

Please turn to page 29. CapEx, depreciation, and R&D expenses remain unchanged from the initial forecast.

This concludes my explanation. Thank you very much.

Ogawa: Thank you. We now move on to CEO Hirai.

Vision 2030



Grow through well-balanced creation of social and economic value


By providing **differentiated materials and solutions**, AGC strives to help realize a **sustainable society and become an excellent company** that grows and evolves continuously.



©AGC Inc. 31

Hirai: I'm Hirai, CEO. I'd like to go over the initiatives for corporate value enhancements, including the forecast for the future. In 2021, I assumed this position of CEO, and I announced the vision for 2030. By providing differentiated materials and solutions, we strive to help realize a sustainable society and become an excellent company that grows and evolves continuously. That is what we aspire to be. To realize this, we are providing both well-balanced creation and social and economic value for growth. Sustainability management and business portfolio transformation are the two important parts of this. In terms of business portfolio transformation, by promoting the ambidextrous approach, we are trying to build a business that is resilient to market fluctuations and has high asset efficiency, growth potential, and carbon efficiency.

Direction of the Business Portfolio Transformation (2)



*: Created based on FY2022 results

** : Based on 2021 emissions per 2022 sales

©AGC Inc.

33

Now on the horizontal axis, we have carbon efficiency. We have ROCE, which is a capital efficiency on the vertical axis. The navy blue, these are the strategic businesses, which are on the top right. Both in terms of carbon efficiency as well as ROCE, it is in a desirable state. As we grow the strategic businesses, in addition to that, we intend to enhance the carbon efficiency and the capital efficiency of other businesses. This is how we intend to make a business portfolio transformation. Now as a result of these initiatives, I'd like to show this slide to you. As our CFO, Miyaji, has mentioned, in terms of strategic business, 2016 onwards, on a consecutive basis, we've been able to increase the sales and profit. However, this fiscal term, we expect to see a dip. However, on a mid- to long-term basis, we do believe the strategic business will grow. Now in terms of the core businesses, they are bound to be affected by market conditions. However, we believe profitability has been on the rise, thanks to price revisions and structural reforms, as you can tell on the bottom right.

Progress in Business Portfolio Transformation (1)

- Strategic business will expand over the medium term, but sales is expected to hit a plateau and profits are expected to decline in 2023.
- While being affected by market conditions, the profitability of the core business has improved and become more stable thanks to price revisions and structural reforms.

Strategic business



Plateaued in 2023

Core business



Improved profitability and stability

Here, I'd like to focus on the medium- to long-term prospects of each business. First, in the strategic business overall for 2023, there will be adjustments due to market conditions, but in the medium to long term, we expect these businesses to grow along with the market expansion. For electronics, EUV mass blanks are robust, but overall business, especially semiconductor and smartphone markets are being affected. We believe that in 2023, we'll see a standstill. As for next year onward, in addition to growth of EUV mask blanks, with the recovery of the semiconductor market, we expect the trajectory to return to growth.













As for life science for this fiscal year, with the loss of the special demand related to the COVID-19-related products as well as reduced inflows of funds for bioventures and a decline in contract sales due to a delay in the launch of a new biopharmaceutical CDMO production line in the US. We'll normalize the new line in the U.S. this year and from 2024 onwards, with the market recovers, we expect the growth trajectory to return to what it used to be.

As for mobility, there has been a delay in the business expansion in terms of CASE technology, but we expect growth with the recovery.

Progress in Business Portfolio Transformation

(3) Core business

- The core businesses have achieved stable profitability and improved asset efficiency.

	Current situation		Medium/Long-term outlook	
 Architectural Glass	The profit improved due to price revisions and structural reforms.		The profitability will remain stable as favorable winds, such as good house renovation demand, will continue.	
 Automotive	The business started to generating profits along with the progress in the revision of pricing policy and structural reforms.		Profitability and asset efficiency are expected to improve as a result of improvements in the macro environment, such as the elimination of the semiconductor shortage, and the promotion of profit improvement measures that are being undertaken.	
 Display	We are reviewing the existing structural reforms and pricing policies.		The profit will improve starting in 2024 as a result of market recovery, structural reforms and pricing policy revisions.	
 Chemicals	<p>【Essential Chemicals】 Although market conditions have not recovered and remain at a low level, a certain level of profit is secured due to high market position.</p> <p>【Performance Chemicals】 The business have been standstill as affected by the semiconductor and smartphone markets.</p>		<p>【Essential Chemicals】 The market will recover gradually, and the profit will pick up.</p> <p>【Performance Chemicals】 The profit will improve as a result of capacity expansion and market recovery.</p>	

©AGC Inc. 36

As for core businesses, as for architectural glass, it used to be we were suffering in this business. But with the price revisions and structural reform, we are seeing a stable situation in terms of earnings, and we are seeing a tailwind for renovation in Europe and Japan. Earnings are expected to remain stable in the future too.


As for automotive, after COVID-19, the difficult situation continued. But from the start of this year, the semiconductor shortage impact on the production delay is gradually recovering. Through the pricing reform and the structural reform, we are seeing the effect of the measures to enhance the profitability that we have implemented in the past. As a result, the asset efficiency improvement and profitability improvement are expected in the future.

As for display, since H2 last year, we have seen a big drop in production volume. But starting this year, we are seeing a gradual recovery in volume. Structural reform is being implemented against that backdrop, and we are also revising our pricing policy so that with the recovery in the market in 2024 onward, we should see the result of the measures.

As for chemicals and essential chemicals, the markets, especially given the situation of the China market — we have not been able to see the recovery. But even in these market conditions, we see a certain level of operating profit. As for performance chemicals, we have been affected by the semiconductor and smartphone markets up to this year, but starting next year for essential chemicals, a gradual recovery in the China and US markets is expected. With that, we expect a gradual recovery. As for performance chemicals, in addition to the market recovery, the capacity expansion is to contribute to the improved profit.

Challenge of improving PBR

- ROE and PBR fluctuations strongly correlated with each other.



Improving and stabilizing ROE is the top priority for PBR improvement.

©AGC Inc. 37

Now what is under focus is the P/B ratio and the issue, the discount of the P/B ratio. In terms of AGC's PBR, we have not been able to exceed 1.0. We have been trying to look at the correlation between ROE and P/B ratio since 2008. As you can tell, these are the plotted ROE and P/B ratios. As you can tell, there's a fairly strong correlation with each other. For P/B ratio improvement, it is essential that we improve and stabilize ROE. We do believe this is a top priority. P/B ratio improvement has long been recognized as an important management issue. In terms of the TSE disclosure request, we have been conducting discussions, including at BOD. Some of the current initiatives are listed here. We announced a ROE target with an awareness of the cost of shareholders' equity, so a stable ROE of 10% by 2030. Also, flexible share buybacks and a stable dividend payout ratio of 40% on a consolidated basis. These have been announced already as current initiatives.

Realization of business management focused on cost of capital and stock price



- PBR improvement has long been recognized as an important management issue.
- TSE disclosure requests will be reviewed internally, including the Board of Directors.

Initiatives and issues to be addressed

[Current initiatives]

- Announced ROE target (stable ROE of 10% by 2030) with an awareness of the cost of shareholders' equity.
- Flexible share buybacks and a stable dividend payout ratio of 40% on a consolidated basis.

[Issues to be addressed]

- We promote business portfolio transformation through aggressive investment in growth businesses. Growth businesses are expanding steadily, but PBR remains low because ROE target cannot be achieved due to restructuring costs, impairment losses, etc.

Current policy

- We aim to achieve a stable ROE of 8% or more as early as possible by expanding the strategic businesses, with the core business serving as a long-term stable earnings base.

©AGC Inc. 38

Now issues to be addressed are listed here. Through our aggressive investment into growth businesses, we have been conducting business portfolio transformation. Growth businesses are expanding steadily. However, the P/B ratio remains low because the ROE target cannot be achieved due to restructuring costs, impairment losses, and et cetera. The current policy is in the bottom. We aim to achieve a stable ROE of 8% or more as early as possible by expanding the strategic businesses with the core business serving as a long-term stable earnings base.

AGC Group's Brand Statement

Never take the easy way out, but confront difficulties
Trust is the best way to inspire people
Strive to develop technologies that will change the world
A sense of mission leads us to advance

For more than a century, AGC has been guided by these founding spirits. Our unique materials, solutions and reliable partnerships have facilitated leading innovations across diverse industries and markets.

Today, by working with others to combine knowledge and advanced technology, we help make ever greater achievements possible, and bring bolder ideas to life

Your Dreams, Our Challenge

Next slide, please. We operate with this AGC Brands brand statement, "Your dreams, our challenge." We will continue to make our challenge to contribute to society. We ask for your continued support. Thank you very much.

[END]